DK2075002T3 - Myoblaster til reparation af urinvejslukkemuskel - Google Patents

Myoblaster til reparation af urinvejslukkemuskel

Info

Publication number
DK2075002T3
DK2075002T3 DK08169379.8T DK08169379T DK2075002T3 DK 2075002 T3 DK2075002 T3 DK 2075002T3 DK 08169379 T DK08169379 T DK 08169379T DK 2075002 T3 DK2075002 T3 DK 2075002T3
Authority
DK
Denmark
Prior art keywords
myoblasts
repair
urinary tract
muscle
tract muscle
Prior art date
Application number
DK08169379.8T
Other languages
English (en)
Inventor
Michael B Chancellor
Johnny Huard
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2075002(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of DK2075002T3 publication Critical patent/DK2075002T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08169379.8T 1998-05-01 1999-04-30 Myoblaster til reparation af urinvejslukkemuskel DK2075002T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8391798P 1998-05-01 1998-05-01
EP05000057A EP1604674B1 (en) 1998-05-01 1999-04-30 Use of myoblasts in the manufacture of a medicament for treating stress urinary incontinence

Publications (1)

Publication Number Publication Date
DK2075002T3 true DK2075002T3 (da) 2013-05-21

Family

ID=22181500

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08169379.8T DK2075002T3 (da) 1998-05-01 1999-04-30 Myoblaster til reparation af urinvejslukkemuskel
DK05000057T DK1604674T3 (da) 1998-05-01 1999-04-30 Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05000057T DK1604674T3 (da) 1998-05-01 1999-04-30 Anvendelse af myoblaster til fremstilling af et medikament til behandling af stressinkontinens

Country Status (8)

Country Link
EP (3) EP1113807B1 (da)
AT (2) ATE369141T1 (da)
AU (1) AU3775799A (da)
CA (1) CA2330660C (da)
DE (2) DE69936785D1 (da)
DK (2) DK2075002T3 (da)
ES (2) ES2319660T3 (da)
WO (1) WO1999056785A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US6706682B2 (en) 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
WO2000066177A1 (en) * 1999-05-03 2000-11-09 Tissuegene Co. GENE THERAPY USING TGF-$g(b)
US6315992B1 (en) 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
US7338655B1 (en) 1999-06-30 2008-03-04 Tissuegene, Inc. Gene therapy using TGF-β
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
CA2380635A1 (en) * 1999-08-19 2001-02-22 Stem Cell Pharmaceuticals, Inc. Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
ATE365045T1 (de) * 2000-04-14 2007-07-15 Univ Pittsburgh Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
WO2002067867A2 (en) * 2001-02-23 2002-09-06 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
CN103230415B (zh) * 2003-04-25 2016-05-04 匹兹堡大学联邦制高等教育 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc）
CA2670949C (en) † 2006-11-28 2015-06-16 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
WO2008076435A1 (en) 2006-12-18 2008-06-26 University Of Pittsburgh Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
CA2674795C (en) 2007-01-11 2016-08-23 University Of Pittsburgh Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
EP2155216A1 (en) * 2007-06-15 2010-02-24 Ethicon, Inc Tissue fragment compositions for the treatment of incontinence
CA2734858C (en) * 2008-08-18 2019-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
WO2014040030A1 (en) * 2012-09-10 2014-03-13 Wake Forest University Health Sciences Urine stem cells for skeletal muscle generation and uses thereof
EP3511412A1 (en) 2018-01-12 2019-07-17 Genethon Genetically engineered hematopoietic stem cell as a platform for systemic protein expression
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
WO2020238961A1 (en) * 2019-05-29 2020-12-03 Institute Of Zoology, Chinese Academy Of Sciences Compositions and use of engineered myogenic cells
WO2024115761A1 (en) 2022-12-01 2024-06-06 Universität Zürich Method of preparing a mass culture of muscle precursor cells (mpcs) and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) * 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
EP0670902A1 (en) 1992-11-25 1995-09-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education cDNA CLONE FOR HUMAN INDUCIBLE NITRIC OXYDE SYNTHASE AND PROCESS FOR PREPARING SAME
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
CA2183167A1 (en) * 1994-12-13 1996-06-20 Peter K. Law Myoblast therapy for mammalian diseases
US6150338A (en) * 1997-02-13 2000-11-21 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for alleviating erectile dysfunction

Also Published As

Publication number Publication date
EP2075002A2 (en) 2009-07-01
WO1999056785A2 (en) 1999-11-11
EP1604674B1 (en) 2008-11-19
EP1113807A2 (en) 2001-07-11
DK1604674T3 (da) 2009-03-23
EP1113807B1 (en) 2007-08-08
CA2330660A1 (en) 1999-11-11
ATE369141T1 (de) 2007-08-15
ES2319660T3 (es) 2009-05-11
DE69936785D1 (de) 2007-09-20
EP2075002A3 (en) 2009-07-08
CA2330660C (en) 2012-04-10
EP1604674A3 (en) 2005-12-21
EP1604674A2 (en) 2005-12-14
DE69939956D1 (de) 2009-01-02
ATE414524T1 (de) 2008-12-15
EP2075002B1 (en) 2013-02-13
AU3775799A (en) 1999-11-23
WO1999056785A3 (en) 2001-04-19
ES2419029T3 (es) 2013-08-19

Similar Documents

Publication Publication Date Title
DK2075002T3 (da) Myoblaster til reparation af urinvejslukkemuskel
DE60126172D1 (de) Prothese für Herniereparatur
DK1404324T3 (da) Prolægemidler af GABA analoger, sammensætninger og anvendelser deraf
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
CA2445062A1 (en) Matched balloon to stent shortening
BR0209110B1 (pt) pràtese de joelho com uma articulaÇço de flexço.
EP1406122A3 (en) Photosensitive composition and acid generator
DE69824092D1 (de) Prothese zur Hernia Reparatur
DK1047406T3 (da) Autoklaverbar farmaceutisk sammensætning indeholdende en chelatdanner
DK1301436T3 (da) Fremgangsmåder til syntese af et oxidationsmiddel samt dets anvendelse
DE60330703D1 (de) Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
PL371464A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
ECSP045075A (es) Endoprotesis vasculares ("stents")"
FR2845917B1 (fr) Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
MA28354A1 (fr) Nouvelles combinaisons d'un agent anti-emetique et d'un inhibiteur de l'enkephalinase
WO2001082820A3 (en) Lingual arch developer
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
FI990649A (fi) Menetelmä päivittää koodigeneraattorin lineaarinen palautesiirtorekisteri
UY26574A1 (es) " procedimiento para la separación enzimática de racematos de derivados de aminometil-aril-ciclohexanol".
AU8566998A (en) Photocurable composition based on acid functional, primary resinous mercaptans
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
BRPI0410868A (pt) composição nutricional e método de inibição da contração de células do músculo liso com a mesma
ES2175279T3 (es) Compuestos de tetrahidrobenzo(a)fluoreno y procedimientos de uso.
DK1755583T3 (da) Anvendelse af neboglamin til behandling af skizofreni